Navigating SEC Comment Letters: Non-GAAP Disclosures and Metrics
Inevitably, companies looking to go public will face the prospect of comment letters from the Securities and Exchange Commission (SEC).
The Ultimate Guide to a Life Sciences IPO
The life sciences industry is in the middle of an IPO boom, with the 10 highest-valued biotech IPOs raising $3.
Get Ahead of Your Next Audit by Implementing ASC 606 Revenue Recognition Standards
Time is running out for any remaining companies to implement the latest ASC 606 revenue recognition standard.
Meet Kelly Provost: A Leader in CFGI’s Life Sciences Capital Markets
Kelly Provost is a leader in CFGI’s Life Sciences Capital Markets practice and has dedicated her career to supporting companies that are trying to cure diseases and save lives, making a difference in the lives of people across the world.
How to Get Paid for Transformation (Shhh, Without Doing It All!)
The sell-side quality-of-earnings (QoE) report has become a critical piece of any private equity transaction.
Navigating SEC Comment Letters: Segment Reporting
When companies are ready to go public, they’re often surprised by the increased reporting demands during and following the period of transition from a private entity.
Meet Angela Barcelos: CFGI’s Risk Advisory Practice Leader
Through hard work and dedication, Angela Barcelos has made a name for herself at CFGI and in the broader financial industry.
Meet Melanie Kavanagh: A Committed Accounting and Finance Leader at CFGI’s SF Office
Melanie Kavanagh’s promotion to Partner has been an achievement in the making since the day she walked in the doors at CFGI in 2012.